Issue 8, 2015

A new quinoxaline-containing peptide induces apoptosis in cancer cells by autophagy modulation

Abstract

The synthesis of a new small library of quinoxaline-containing peptides is described. After cytotoxic evaluation in four human cancer cell lines, as well as detailed biological studies, it was found that the most active compound, RZ2, promotes the formation of acidic compartments, where it accumulates, blocking the progression of autophagy. Further disruption of the mitochondrial membrane potential and an increase in mitochondrial ROS was observed, causing cells to undergo apoptosis. Given its cytotoxic activity and protease-resistant features, RZ2 could be a potential drug candidate for cancer treatment and provide a basis for future research into the crosstalk between autophagy and apoptosis and its relevance in cancer therapy.

Graphical abstract: A new quinoxaline-containing peptide induces apoptosis in cancer cells by autophagy modulation

Supplementary files

Article information

Article type
Edge Article
Submitted
13 Jan 2015
Accepted
18 May 2015
First published
20 May 2015
This article is Open Access

All publication charges for this article have been paid for by the Royal Society of Chemistry
Creative Commons BY license

Chem. Sci., 2015,6, 4537-4549

A new quinoxaline-containing peptide induces apoptosis in cancer cells by autophagy modulation

R. Zamudio-Vázquez, S. Ivanova, M. Moreno, M. I. Hernandez-Alvarez, E. Giralt, A. Bidon-Chanal, A. Zorzano, F. Albericio and J. Tulla-Puche, Chem. Sci., 2015, 6, 4537 DOI: 10.1039/C5SC00125K

This article is licensed under a Creative Commons Attribution 3.0 Unported Licence. You can use material from this article in other publications without requesting further permissions from the RSC, provided that the correct acknowledgement is given.

Read more about how to correctly acknowledge RSC content.

Social activity

Spotlight

Advertisements